Traws Pharma Inc (TRAW) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Traws Pharma Inc stock (TRAW) is currently trading at $2.00. Traws Pharma Inc PS ratio (Price-to-Sales) is 6.23. Analyst consensus price target for TRAW is $8.00. WallStSmart rates TRAW as Sell.
- TRAW PE ratio analysis and historical PE chart
- TRAW PS ratio (Price-to-Sales) history and trend
- TRAW intrinsic value — DCF, Graham Number, EPV models
- TRAW stock price prediction 2025 2026 2027 2028 2029 2030
- TRAW fair value vs current price
- TRAW insider transactions and insider buying
- Is TRAW undervalued or overvalued?
- Traws Pharma Inc financial analysis — revenue, earnings, cash flow
- TRAW Piotroski F-Score and Altman Z-Score
- TRAW analyst price target and Smart Rating
Traws Pharma Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Traws Pharma Inc (TRAW) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Traws Pharma Inc (TRAW) Key Strengths (1)
Revenue surging 4695.00% year-over-year
Supporting Valuation Data
Traws Pharma Inc (TRAW) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 6.2x annual revenue
Premium pricing at 3.7x book value
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Traws Pharma Inc (TRAW) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 4695.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Market Cap. Some valuation metrics including Price/Sales (6.23), Price/Book (3.71) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -1060.00%, Operating Margin at -555.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1060.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 4695.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TRAW Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TRAW's Price-to-Sales ratio of 6.23x trades 31% below its historical average of 9.07x (61th percentile). The current valuation is 92% below its historical high of 74.53x set in Sep 2018, and Infinity% above its historical low of 0x in Jan 2012. Over the past 12 months, the PS ratio has expanded from ~4.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Traws Pharma Inc (TRAW) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Traws Pharma Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 3M with 4695% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 4695% YoY, reaching 3M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 81% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Traws Pharma Inc maintain 4695%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.75, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Traws Pharma Inc.
Bottom Line
Traws Pharma Inc is a high-conviction growth story with revenue accelerating at 4695% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:25:29 AM
About Traws Pharma Inc(TRAW)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. The company is headquartered in Newtown, Pennsylvania.